Eli Lilly Sees Mixed Q4 Results Despite Strong Demand for Weight Loss and Diabetes Drugs
Eli Lilly reported mixed quarterly results, with sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soaring, but lower realized prices overshadowing gains. Demand for Eli Lilly’s incretin drugs has outpaced supply in the US over the past year. The company’s quarter earnings topped estimates, but fell short on sales due to … Read more